Apnimed’s Post

Couldn't be more proud of our mighty team for this milestone!

We are thrilled to announce the early completion of patient enrollment for our SynAIRgy Phase 3 study of AD109, our investigational oral treatment for obstructive sleep apnea (OSA). 🎉 A heartfelt thank you to all the patients who are participating in this crucial trial and to the dedicated staff at our trial sites. Your commitment is bringing us closer to potentially redefining the standard of care for OSA. We know more treatment options are desperately needed. AD109 aims to address the root cause of OSA, and our mission is to make it become the first FDA-approved oral therapy to enhance oxygenation and improve patient outcomes. Stay tuned for more updates as we continue on this journey to transform OSA treatment. #OSA #SleepApnea #AD109 #ClinicalTrials

Our team will present our latest study findings on the prevalence of obesity hypoventilation syndrome (OHS) at #ERSCongress. Join us for our poster presentation on Sunday, September 8 at 8 a.m. CEST. We look forward to engaging with fellow respiratory experts and hearing the latest perspectives and findings in respiratory medicine and science.    Learn more: https://lnkd.in/g6aFtcFx

Help us welcome Chasty Daniels, MA as our new Principal Clinical Trial Manager. Chasty comes to us with over a decade of experience ranging from research operations assistance to global trial management and will help build and maintain Apnimed clinical trials. Welcome aboard, Chasty!  Explore careers at Apnimed. https://bit.ly/4dO72Bt

We’re thrilled to share Michele Miller, PharmD has joined our team as Director, Medical Information. With over a decade of experience in the field, Michele will play a key role in elevating relationships with health care personnel and the patient experience while building a best-in-industry Medical Information capability at Apnimed. Welcome, Michele! Interested in working with us? Explore more Apnimed careers. https://bit.ly/4dO72Bt

“Sleep apnea affects millions and spares no one––even elite athletes at the top of their game,” says our Senior Vice President of Clinical Development, John Cronin, MD #Paris2024 Swedish handball star Jim Gottfridsson is no exception. Like many living with obstructive #SleepApnea (OSA), he assumed his extreme fatigue was because of parenthood and his profession. However, with encouragement from his wife, he underwent a sleep analysis that resulted in an #OSA diagnosis.  More awareness of the symptoms of OSA is imperative so people can be accurately diagnosed and treated. Read more about his story with OSA: https://bit.ly/3Yy5EOJ 

In the United States alone, more than 36 million people living with obstructive sleep apnea (OSA) remain undiagnosed and untreated.     To help spread awareness of OSA symptoms, Project Sleep is launching its first #SleepApneaSquad broadcast, led by sleep apnea advocates and experts.    Tune into the live broadcast on YouTube today at 2 p.m. ET: https://bit.ly/3yvUaAL

Many people living with obstructive sleep apnea (OSA) delay seeking out diagnosis and treatment for a variety of reasons, from lack of awareness to low acceptance of current treatment options, with at least 80% of people with OSA remaining undiagnosed.    To address this concerning public health gap, Project Sleep has launched the #SleepApneaSquad, a new educational initiative backed by leading clinicians and advocates to help people navigate the complex OSA journey.  We’re thrilled to support this much needed program which will help support unmet needs in the OSA community. Learn more: https://prn.to/46puNwU